Side by side
Compare compounds
Add up to three compounds with the compare button on any library card or compound page.
Written comparison available
Tirzepatide vs retatrutide
Swipe the table sideways to see every compound.
| Attribute |  |  |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | A Human trial evidence | A Human trial evidence |
| Regulatory status | Investigational | FDA-approved |
| Human amounts | Trial dosesDosing reference Study durations | FDA labelDosing reference Study durations |
| Format | Lyophilized vial | Lyophilized vial |
| Type | Single compound | Single compound |
| Molecular formula | Not listed | C225H348N48O68 |
| Molecular weight | Not listed | 4,813 g/mol |
| CAS number | Not listed | Not listed |
| Sequence | Not listed | Not listed |
| References | 16 | 8 |
| Summary | Retatrutide is an investigational peptide that acts on three receptors (glucagon, GIP and GLP-1) and is given by weekly subcutaneous injection in clinical trials. Published phase 2 and 2026 phase 3 randomized trials have reported large mean body-weight reductions and HbA1c reductions versus placebo, with gastrointestinal events the most commonly reported adverse events. It is not approved for any use, and this entry summarizes the published and registered trials for research reference only. | Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors and is approved by the FDA for type 2 diabetes (Mounjaro), and for chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound). Randomized phase 3 trials have studied its effects on glycemic control, body weight and sleep apnea severity, with gastrointestinal events the most commonly reported adverse reactions. This entry summarizes the FDA labels and published trials for research reference only. |